hi-To The Moon - Tiger Brokers Online Investing Community - To The Moon

Like
Comment
Favorite

家永
2021-04-28

hi

Zhaoke Ophthalmology-B has a winning rate of 25% for one lot, and you can secure one lot if you subscribe for 10 lots

4月28日消息，本周三兆科眼科-B发布公告，公司发行约1.24亿股，每股定价16.8港元，每手500股，预期4月29日上市。公开发售阶段兆科眼科-B获56倍认购，分配至公开发售的发售股份最终数目为49

Zhaoke Ophthalmology-B has a winning rate of 25% for one lot, and you can secure one lot if you subscribe for 10 lots

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Like

Report

Comment

Top
Latest

empty

No comments yet

Most Discussed

{"i18n":{"language":"en_US"},"data":{"magic":2,"id":100382385,"tweetId":"100382385","gmtCreate":1619581134647,"gmtModify":1704726303908,"author":{"id":3576725256218989,"idStr":"3576725256218989","authorId":3576725256218989,"authorIdStr":"3576725256218989","name":"家永","avatar":"https://static.tigerbbs.com/b2bd55700e996ad58a5f66e4394f3c0d","vip":1,"userType":1,"introduction":"","boolIsFan":false,"boolIsHead":false,"crmLevel":11,"crmLevelSwitch":0,"individualDisplayBadges":[],"fanSize":0,"starInvestorFlag":false},"themes":[],"images":[],"coverImages":[],"extraTitle":"","html":"<html><head></head><body><p>hi</p></body></html>","htmlText":"<html><head></head><body><p>hi</p></body></html>","text":"hi","highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"link":"https://ttm.financial/post/100382385","repostId":1155419221,"repostType":4,"repost":{"id":"1155419221","kind":"news","weMediaInfo":{"introduction":"为用户提供金融资讯、行情、数据，旨在帮助投资者理解世界，做投资决策。","home_visible":1,"media_name":"老虎资讯综合","id":"102","head_image":"https://static.tigerbbs.com/8274c5b9d4c2852bfb1c4d6ce16c68ba"},"pubTimestamp":1619570931,"share":"https://ttm.financial/m/news/1155419221?lang=en_US&edition=fundamental","pubTime":"2021-04-28 08:48","market":"hk","language":"zh","title":"Zhaoke Ophthalmology-B has a winning rate of 25% for one lot, and you can secure one lot if you subscribe for 10 lots","url":"https://stock-news.laohu8.com/highlight/detail?id=1155419221","media":"老虎资讯综合","summary":"4月28日消息，本周三兆科眼科-B发布公告，公司发行约1.24亿股，每股定价16.8港元，每手500股，预期4月29日上市。公开发售阶段兆科眼科-B获56倍认购，分配至公开发售的发售股份最终数目为49","content":"<p>News on April 28, this Wednesday<a href=\"https://laohu8.com/S/06622\">Zhaoke Ophthalmology-B</a>According to the announcement, the company issued about 124 million shares, priced at HK $16.8 per share, with 500 shares per lot, and is expected to be listed on April 29.<img src=\"https://static.tigerbbs.com/01b92e9bd3171ffb2457dc1b91f4f602\" tg-width=\"664\" tg-height=\"549\" referrerpolicy=\"no-referrer\">During the public offering stage, Zhaoke Ophthalmology-B was subscribed 56 times, and the final number of offer shares allocated to the public offering was 49.427 million shares, accounting for 40% of the total number of offer shares (before any over-allotment option is exercised). A total of 111,183 valid applications were received, with a winning rate of 25% for one lot, and 10 subscriptions were secure for one lot.</p><p>In addition, the international offering was oversubscribed, and the final number of shares offered was 74.1405 million shares, equivalent to 60% of the total number of shares offered.</p><p><b>Distribution result:</b></p><p>Group A has 500 shares per lot, and the admission fee is HK $8,484.65. The winning rate of one lot is 25%, and if you subscribe for 10 lots, you will win one lot.</p><p>The head of Group B is 300,000 shares (600 lots), the funds required for subscription are approximately HK $5,090,788.08, and 25,500 shares (51 lots) are allocated.<img src=\"https://static.tigerbbs.com/4698be44707b7f7a568fc24b1cfa2592\" tg-width=\"715\" tg-height=\"822\" referrerpolicy=\"no-referrer\"><img src=\"https://static.tigerbbs.com/6b70e8623eed25bc759fc685cd6438aa\" tg-width=\"725\" tg-height=\"629\" referrerpolicy=\"no-referrer\"></p><p>The net proceeds of approximately HK $1.942 billion will be used for the following purposes: approximately 32% will be used for clinical development and commercialization of core products; Approximately 46% will provide funds for the ongoing research and development activities and commercialization of other drug candidates under development; Approximately 7% will be used for production line expansion at the advanced production facility in Nansha to prepare for product launch in the coming year; Approximately 5% will fund business development activities and the expansion of drug candidates; Approximately 10% will be used for working capital and other general corporate purposes.</p><p>It is reported that Zhaoke Ophthalmology is an ophthalmic pharmaceutical company that has established a comprehensive ophthalmic drug pipeline containing 25 drug candidates through independent development or licensing introduction, covering most of the major ophthalmic indications affecting the anterior and posterior segments of the eye.</p><p>According to the prospectus, the company initially focuses its strategy on China's five major ophthalmic indications (in terms of market potential), including dry eye syndrome (DED), wet age-related macular degeneration (wAMD), diabetic macular edema (DME), myopia and glaucoma. According to CIC, the company has one of the most comprehensive ophthalmic drug pipelines in China</p><p>It is worth noting that the company has received the support of star institutional investors, including Singapore Government Investment Corporation, Hillhouse Capital, TPG, Loyalty Valley Capital, Aobo Capital and Aier Eye Hospital. And<a href=\"https://laohu8.com/S/00950.HK\">Lee's Pharmaceutical Factory</a>Before the IPO, it held 34.1% of the shares of Zhaoke Ophthalmology and was the company's single largest shareholder.</p><p>In terms of financial data, during the Track Record Period, the company has not yet made a profit and incurred operating losses. Loss for the year expanded from RMB122 million in 2019 to RMB727 million in 2020.</p><p>In terms of industry, China's ophthalmic drug market is in its infancy and is now growing exponentially with a rapid trend. The market size of ophthalmic drugs in China grew from US $1.8 billion in 2015 to US $2.6 billion in 2019, with a compound annual growth rate of 9.3%. It is expected to further grow from a CAGR of 18.6% in 2019 to US $7.2 billion in 2025 and from a CAGR of 22.9% in 2025 to US $20.2 billion in 2030, exceeding the growth of the global ophthalmic drug market during the same period</p><p>China's ophthalmic drug market is relatively fragmented, and there is a lack of companies that focus on ophthalmology with the intention and ability to systematically solve problems in this professional field. For most market players, ophthalmic drug assets represent only a small portion of their business. Only a few companies, most of which are multinational companies, have drug portfolios covering major ophthalmic diseases affecting the anterior and posterior segments of the eye.</p>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Zhaoke Ophthalmology-B has a winning rate of 25% for one lot, and you can secure one lot if you subscribe for 10 lots</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nZhaoke Ophthalmology-B has a winning rate of 25% for one lot, and you can secure one lot if you subscribe for 10 lots\n</h2>\n<h4 class=\"meta\">\n<a class=\"head\" href=\"https://laohu8.com/wemedia/102\">\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/8274c5b9d4c2852bfb1c4d6ce16c68ba);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">老虎资讯综合 </p>\n<p class=\"h-time smaller\">2021-04-28 08:48</p>\n</div>\n</a>\n</h4>\n</header>\n<article>\n<p>News on April 28, this Wednesday<a href=\"https://laohu8.com/S/06622\">Zhaoke Ophthalmology-B</a>According to the announcement, the company issued about 124 million shares, priced at HK $16.8 per share, with 500 shares per lot, and is expected to be listed on April 29.<img src=\"https://static.tigerbbs.com/01b92e9bd3171ffb2457dc1b91f4f602\" tg-width=\"664\" tg-height=\"549\" referrerpolicy=\"no-referrer\">During the public offering stage, Zhaoke Ophthalmology-B was subscribed 56 times, and the final number of offer shares allocated to the public offering was 49.427 million shares, accounting for 40% of the total number of offer shares (before any over-allotment option is exercised). A total of 111,183 valid applications were received, with a winning rate of 25% for one lot, and 10 subscriptions were secure for one lot.</p><p>In addition, the international offering was oversubscribed, and the final number of shares offered was 74.1405 million shares, equivalent to 60% of the total number of shares offered.</p><p><b>Distribution result:</b></p><p>Group A has 500 shares per lot, and the admission fee is HK $8,484.65. The winning rate of one lot is 25%, and if you subscribe for 10 lots, you will win one lot.</p><p>The head of Group B is 300,000 shares (600 lots), the funds required for subscription are approximately HK $5,090,788.08, and 25,500 shares (51 lots) are allocated.<img src=\"https://static.tigerbbs.com/4698be44707b7f7a568fc24b1cfa2592\" tg-width=\"715\" tg-height=\"822\" referrerpolicy=\"no-referrer\"><img src=\"https://static.tigerbbs.com/6b70e8623eed25bc759fc685cd6438aa\" tg-width=\"725\" tg-height=\"629\" referrerpolicy=\"no-referrer\"></p><p>The net proceeds of approximately HK $1.942 billion will be used for the following purposes: approximately 32% will be used for clinical development and commercialization of core products; Approximately 46% will provide funds for the ongoing research and development activities and commercialization of other drug candidates under development; Approximately 7% will be used for production line expansion at the advanced production facility in Nansha to prepare for product launch in the coming year; Approximately 5% will fund business development activities and the expansion of drug candidates; Approximately 10% will be used for working capital and other general corporate purposes.</p><p>It is reported that Zhaoke Ophthalmology is an ophthalmic pharmaceutical company that has established a comprehensive ophthalmic drug pipeline containing 25 drug candidates through independent development or licensing introduction, covering most of the major ophthalmic indications affecting the anterior and posterior segments of the eye.</p><p>According to the prospectus, the company initially focuses its strategy on China's five major ophthalmic indications (in terms of market potential), including dry eye syndrome (DED), wet age-related macular degeneration (wAMD), diabetic macular edema (DME), myopia and glaucoma. According to CIC, the company has one of the most comprehensive ophthalmic drug pipelines in China</p><p>It is worth noting that the company has received the support of star institutional investors, including Singapore Government Investment Corporation, Hillhouse Capital, TPG, Loyalty Valley Capital, Aobo Capital and Aier Eye Hospital. And<a href=\"https://laohu8.com/S/00950.HK\">Lee's Pharmaceutical Factory</a>Before the IPO, it held 34.1% of the shares of Zhaoke Ophthalmology and was the company's single largest shareholder.</p><p>In terms of financial data, during the Track Record Period, the company has not yet made a profit and incurred operating losses. Loss for the year expanded from RMB122 million in 2019 to RMB727 million in 2020.</p><p>In terms of industry, China's ophthalmic drug market is in its infancy and is now growing exponentially with a rapid trend. The market size of ophthalmic drugs in China grew from US $1.8 billion in 2015 to US $2.6 billion in 2019, with a compound annual growth rate of 9.3%. It is expected to further grow from a CAGR of 18.6% in 2019 to US $7.2 billion in 2025 and from a CAGR of 22.9% in 2025 to US $20.2 billion in 2030, exceeding the growth of the global ophthalmic drug market during the same period</p><p>China's ophthalmic drug market is relatively fragmented, and there is a lack of companies that focus on ophthalmology with the intention and ability to systematically solve problems in this professional field. For most market players, ophthalmic drug assets represent only a small portion of their business. Only a few companies, most of which are multinational companies, have drug portfolios covering major ophthalmic diseases affecting the anterior and posterior segments of the eye.</p>\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"https://static.tigerbbs.com/6b69e234a63c2c0a69ccede7b0faaa18","relate_stocks":{"06622":"兆科眼科-B"},"is_english":false,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1155419221","content_text":"4月28日消息，本周三兆科眼科-B发布公告，公司发行约1.24亿股，每股定价16.8港元，每手500股，预期4月29日上市。公开发售阶段兆科眼科-B获56倍认购，分配至公开发售的发售股份最终数目为4942.7万股，占发售股份总数的40%（任何超额配股权获行使前）。合共接获111183份有效申请，一手中签率25%，认购10手稳中一手。此外，国际发售获超额认购，发售股份最终数目为7414.05万股，相当于发售股份总数的60%。分配结果：甲组每手500股，入场费8484.65港元。一手中签率25%，认购10手稳中一手。乙组头为300,000股（600手），申购所需资金约5090788.08港元，获配25500股（51）手。所得款项净额约19.42亿港元将用作以下用途：约32%将用于核心产品的临床开发及商业化；约46%将为其他在研候选药物的持续研发活动及商业化提供资金；约7%将用于位于南沙的先进生产设施进行生产线扩张，以筹备未来年度的产品上市；约5%将为业务开发活动及在研药物的扩展提供资金；约10%将用作营运资金及其他一般企业用途。据悉，兆科眼科是一间眼科制药公司，目前已通过自主开发或许可引进已建立起包含25种候选药物的全面眼科药物管线，涵盖影响眼前节及眼后节的多数主要眼科适应症。根据招股书，公司初步将策略重心放在中国五大眼科适应症（就市场潜力而言）上，包括干眼症(DED)、湿性老年黄斑部病变(wAMD)、糖尿病黄斑水肿(DME)、近视及青光眼。根据灼识的资料，公司拥有中国最全面的眼科药物管线之一值得注意的是，公司已获得明星机构投资者的支持，包括新加坡政府投资公司、高瓴资本、TPG、正心谷资本、奥博资本及爱尔眼科医院等。而李氏大药厂于IPO前持有兆科眼科34.1%的股份，为公司单一最大股东。财务数据方面，于往绩记录期间，公司尚未盈利并产生经营亏损。年内亏损由2019年的人民币1.22亿元扩大至2020年的人民币7.27亿元。行业方面，中国眼科药物市场正处于起步阶段，现以迅猛的态势呈指数增长。中国眼科药物的市场规模由2015年的18亿美元增长至2019年的26亿美元，复合年增长率为9.3%。预计由2019年按复合年增长率18.6%进一步增长至2025年的72亿美元及由2025年按复合年增长率22.9%增长至2030年的202亿美元，超过同期全球眼科药物市场的增长中国眼科药物市场较为分散，缺乏有意向及能力系统地解决该专业领域难题且专注于眼科的公司。对于大多数市场参与者而言，眼科药物资产仅占其业务的一小部分。仅有少数几家公司拥有涵盖影响眼睛前节及后节主要眼科疾病的药物组合，其中大部分为跨国企业。","news_type":1,"symbols_score_info":{"06622":0.9}},"isVote":1,"tweetType":1,"viewCount":3429,"commentLimit":10,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"symbols":[],"verified":2,"subType":0,"readableState":1,"langContent":"EN","currentLanguage":"EN","warmUpFlag":false,"orderFlag":false,"shareable":true,"causeOfNotShareable":"","featuresForAnalytics":[],"commentAndTweetFlag":false,"andRepostAutoSelectedFlag":false,"upFlag":false,"length":2,"xxTargetLangEnum":"ORIG"},"commentList":[],"hasMoreComment":false,"orderType":2}